Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopregnanolone in Chronic Complex TBI
NCT04003285Phase 2Not yet recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Dec 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brexanolone in traumatic brain injury (TBI), major depressive disorder (MDD), pain, sponsored by VA Office of Research & Development. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
brexanolone
03
Conditions
traumatic brain injury (TBI)major depressive disorder (MDD)pain
Beyond the preview
Go deeper on NCT04003285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04003285.